Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2022 Financial Results and Business Update on Thursday, August 4

Rhea-AI Summary

Eiger BioPharmaceuticals, Inc. (EIGR) will host a live conference call on August 4, 2022, at 4:30 PM ET to discuss its Q2 2022 financial results and provide a business update. The call and webcast will be accessible via the company's website, with a replay available for 90 days. Eiger focuses on developing innovative therapies for hepatitis delta virus and other serious diseases, boasting a robust pipeline, including two first-in-class therapies in Phase 3 trials. All Eiger's rare disease programs have received FDA breakthrough therapy designation.

Positive

• Eiger has two first-in-class therapies for HDV in Phase 3 trials.
• All five Eiger rare disease programs hold FDA breakthrough therapy designation.

Negative

• None.

-  Live Conference Call and Webcast at 4:30 PM ET  -

PALO ALTO, Calif., July 28, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, August 4, 2022 at 4:30 PM ET to discuss its second quarter 2022 financial results and provide a business update. 

The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com. To participate in the live call by phone, please register in advance at https://register.vevent.com/register/BIfd526d893fcb47fc96359096e28232bb to receive the dial-in number and unique passcode to access the call. The webcast will be archived and available for replay for at least 90 days after the event. 

About Eiger  
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA breakthrough therapy designation. 

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.  

Investors: 
Sylvia Wheeler 
Wheelhouse Life Science Advisors 
swheeler@wheelhouselsa.com 

Media: 
Sarah Mathieson 
SVP, Corporate Affairs 
smathieson@eigerbio.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2022-financial-results-and-business-update-on-thursday-august-4-301594940.html

SOURCE Eiger BioPharmaceuticals, Inc.

FAQ

When is Eiger BioPharmaceuticals' Q2 2022 conference call?

Eiger BioPharmaceuticals' Q2 2022 conference call is scheduled for August 4, 2022, at 4:30 PM ET.

What will be discussed during Eiger's conference call?

The conference call will cover Eiger BioPharmaceuticals' Q2 2022 financial results and provide a business update.

How can I access Eiger BioPharmaceuticals' conference call?

You can access the conference call live or on replay through the Eiger BioPharmaceuticals website.

What is Eiger's focus in biopharmaceuticals?

Eiger is focused on developing innovative therapies for hepatitis delta virus and other serious diseases.